Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 28;21(11):3849.
doi: 10.3390/ijms21113849.

Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors

Andrea Cimini  1 , Maria Ricci  1 , Agostino Chiaravalloti  1   2 , Luca Filippi  3 , Orazio Schillaci  1   2
Affiliations
Review

Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors

Andrea Cimini et al. Int J Mol Sci. .

Abstract

The use of theragnostic radiopharmaceuticals in nuclear medicine has grown rapidly over the years to combine the diagnosis and therapy of tumors. In this review, we performed web-based and desktop literature research to investigate and explain the potential role of theragnostic imaging in pediatric oncology. We focused primarily on patients with aggressive malignancies such as neuroblastoma and brain tumors, to select patients with the highest chance of benefit from personalized therapy. Moreover, the most critical and groundbreaking applications of radioimmunotherapy in children's oncology were examined in this peculiar context. Preliminary results showed the potential feasibility of theragnostic imaging and radioimmunotherapy in pediatric oncology. They revealed advantages in the management of the disease, thereby allowing an intra-personal approach and adding new weapons to conventional therapies.

Keywords: neuroblastoma; nuclear medicine; pediatric brain tumors; pediatric tumors; personalized therapy; positron emission tomography; radioimmunotherapy; radiopharmaceuticals; single-photon emission computed tomography; theragnostics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pre-therapeutic staging in a 4-year-old child with neuroblastoma, performed with 123I MIBG scintigraphy/ single-photon emission computed tomography (SPECT). Planar images (A, anterior; B, posterior) show high uptake of the tracer in the right adrenal gland (white arrow), corresponding to the primary site of the tumor. Moreover, SPECT images of the skull (C–F) demonstrate the presence of metastasis in the occipital bone. Figures E and F display the physiological activities in the salivary glands and in the heart.
Figure 2
Figure 2
A 13-year-old boy suffering from hypertension, with evidence of slightly increased levels of catecholamine metabolites in urine. 123I-MIBG scintigraphy was carried out for the suspicion of pheochromocytoma. Whole Body scan in anterior (A) and posterior (B), abdominal planar (C, anterior; D, posterior) did not show any area of abnormal tracer uptake. Co-registered corresponding axial (E) and coronal (F) SPECT/MRI images confirmed the absence of pathological hyperactive masses in both adrenal glands.
Figure 3
Figure 3
A 17-year-old male with mental retardation due to perinatal hypoxia, suffering from carcinoid syndrome due to ileal NET with hepatic metastases. Since symptomatology persisted despite somatostatin analog therapy and CT gave evidence of tumor progression, PRRT with 177Lu-DOTATATE was considered. Whole Body scan in anterior (A) and posterior (B) view, as well as the planar (C, anterior; D, posterior), acquired with gamma camera centered on the 177Lu photopeak at 113 KeV, well-demonstrated tracer incorporation both in the tumor (C,D, white arrow) and in the liver lesions (C,D, white-bordered arrow). Three further focuses of increased accumulation of the radiopharmaceutical are visible under the primary tumor in the pelvic region, especially evident in the anterior view (C), to be referred to peritoneal carcinomatosis.
See this image and copyright information in PMC

References

    1. Kelly J.M., Amor-Coarasa A., Nikolopolou A., Kim D., Williams C.J., Vallabhajosula S., Babich J.W. Assessment of PSMA Targeting Ligands Bearing Novel Chelates with Application to Theranostics: Stability and Complexation Kinetics of 68Ga3+, 111In3+, 177Lu3+ and 225Ac3. Nucl. Med. Biol. 2017;55:38–46. doi: 10.1016/j.nucmedbio.2017.10.001. - DOI - PubMed
    1. Baiu D.C., Marsh I.R., Boruch A.E., Shahi A., Bhattacharya S., Jeffery J.J., Zhao Q., Hall L.T., Weichert J.P., Bednarz B.P., et al. Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog. J. Nucl. Med. 2018;59:244–250. doi: 10.2967/jnumed.117.193748. - DOI - PMC - PubMed
    1. Pruis I.J., Van Dongen G.A.M.S., Veldhuijzen van Zanten S.E.M. The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors. Int. J. Mol. Sci. 2020;21:1029. doi: 10.3390/ijms21031029. - DOI - PMC - PubMed
    1. Yordanova A., Eppard E., Kürpig S., Bundschuh R.A., Schönberger S., Gonzalez-Carmona M., Feldmann G., Ahmadzadehfar H., Essler M. Theranostics in Nuclear Medicine Practice. Onco Targets Ther. 2017;10:4821–4828. doi: 10.2147/OTT.S140671. - DOI - PMC - PubMed
    1. Bernier J. Immuno-oncology: Allying Forces of Radio- And Immuno-Therapy to Enhance Cancer Cell Killing. Crit. Rev. Oncol. Hematol. 2016;108:97–108. doi: 10.1016/j.critrevonc.2016.11.001. - DOI - PubMed

MeSH terms